Drug
Lad191
Lad191: highest development phase Phase 2, developed by Almirall. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Almirall
Trials
| Drug | Phase | Indication |
|---|---|---|
| LAD191 NCT07151937 | Phase 2 | Hidradenitis Suppurativa |
| LAD191 NCT06488209 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Lad191 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.